Remove 2021 Remove Adverse Reactions Remove FDA
article thumbnail

Wegovy vs. Mounjaro side effects

The Checkup by Singlecare

However, the Food and Drug Administration (FDA) has approved them for different purposes: Wegovy is approved as a weight loss medication, and Mounjaro is approved as a Type 2 diabetes treatment. Mounjaro’s active ingredient, tirzepatide, is sold as an FDA-approved weight loss drug under the name Zepbound.

Dosage 52
article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

In 2014, the US FDA approved this regimen, and it features in the latest WHO guidelines for LTBI treatment. In 2021, Dorman et al demonstrated non-inferiority when moxifloxacin was paired with high-dose rifapentine, isoniazid, and pyrazinamide, resulting in the first four-month regimen approved by both the WHO and the U.S

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

Drug Topics

The FDA approved clesrovimab-cfor (Enflonsia) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season, Merck announced in a release. The most common adverse reactions were injection-site erythema, injection-site swelling and rash.

FDA 430
article thumbnail

Is compounded semaglutide safe?

The Checkup by Singlecare

In fact, the Food and Drug Administration (FDA) says consumers should exercise a lot of caution when considering using a compounded drug. Ozempic is arguably the most popular semaglutide drug, not because of its FDA-approved use for treating Type 2 diabetes but because of the amount of weight people have lost while taking it.

article thumbnail

FDA approves first gene therapy for Haemophilia B

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec), the first gene therapy for adults with Haemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes.

FDA 128
article thumbnail

US FDA approves Amgen-AstraZeneca’s Tezspire for asthma treatment

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval to Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko) for self-administration using a single-use, pre-filled pen for severe asthma patients aged 12 years and above. Pharyngitis, arthralgia, and back pain are the most common adverse reactions of the antibody.

FDA 59
article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

This can be achieved by reducing the burden of adverse reactions or by optimising benefits through patient selection (eg, contraindications, recommendations of use, warnings, concomitant medicine[s], or certain test parameters) and treatment management (eg, specific dosing regimen, relevant testing, patient follow-up).